Citations

Clear

107 citation(s) found for "Scheithauer, Bernd".

Malignant Cranial Nerve Sheath Tumor (MCNST): A clinicopathologic study of 13 cases
Erdogan, Siebel, Scheithauer, Bernd W., Burger, Peter C. , Woodruff, James M., Hirose, Takanori , Spinner, Robert J. , Rodríguez, Fausto J.

Mayo Clinic

The FASEB Journal | March 20, 2020 | Volume: 21 | Issue: 5 | Pages: No page available

10.1096/fasebj.21.5.a27-a Get It

Malignant nerve sheath tumors involving cranial nerves are rare. We identified 13 cases of MCNST arising in cranial nerve or from benign nerve sheath tumors, all but three being intracranial. The patients included 10 males and 3 females, one pediatric (5 years) and the remainder ranging in age from 23 to 69 years (mean, 40). The vestibular (n=5) and vagal nerves (n=3) were favored sites, followed by posterior fossa (n=2), facial nerve (n=1), frontal lobe parenchyma (n=1) and the lateral ventricle (n=1). Some patients were known to have NF1(n=3) or probable NF2 (n=1). Three tumors arose in transition from a conventional schwannoma and one from a plexiform neurofibroma. The majority of the tumors (n=11) were high grade (5 WHO III and 6 WHO IV) lesions. Immunohistochemistry was performed in 11 cases; S‐100 protein reactivity was diffuse (n=1), partial (n=2), focal (n=5) or negative (n=3). Collagen IV was also diffuse (n=2), partial (n=3), focal (n=5) or negative (n=1). p53 protein staining was high (n=7), moderate (n=2), or low (n=2). Clinical follow‐up was available in 10 cases; of the 8 patients who died, six patients did so within six months of surgery, and two within three years. Only one tumor, a grade IV MCNST with heterologous bone formation, developed extensive spinal leptomeningeal drop metastases. The one pediatric patient is alive at 8 years. No clinically apparent systemic metastases were encountered.
Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study.
Cairncross, J. Gregory , Wang, Meihua , Shaw, Edward G. , Jenkins, Robert B. , Scheithauer, Bernd W., Brachman, David, Buckner, Jan C. , Fink, Karen, Souhami, Luís, Curran, Walter J. , Laperrière, Normand , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | March 11, 2020 | Volume: 30 | Issue: 15_suppl | Pages: 2008b-2008b

10.1200/jco.2012.30.15_suppl.2008b Get It

2008b Background: Anaplastic oligodendrogliomas, pure (AO) and mixed (AOA), are chemosensitive tumors, especially if co-deleted for chromosomes 1p and 19q, but whether addition of CT to RT prolongs overall survival (OS), is unknown. Methods: In the RTOG 9402 Phase III trial, patients (pts) with AO/AOA were randomly assigned to PCV [procarbazine, CCNU (lomustine) and vincristine] followed by immediate RT vs. immediate RT alone. Early analysis showed no OS benefit for the PCV+RT group but combined therapy was associated with a longer progression-free survival (PFS). It also showed that the finding of 1p/19q co-deletion was associated with a longer OS independent of treatment. The current analysis has a median follow up of 11.3 years (yrs). Results: Two hundred ninety-one patients were randomized, 148 to PCV+RT and 143 to RT. PCV+RT was associated with longer PFS [2.5 vs. 1.7 yrs, hazard ratio (HR) 0.68, 95% confidence interval (CI) (0.53, 0.88), P = 0.003] and the 1p/19q co-deletion with a longer Median Survival Time (MST) [8.7 vs. 2.7 yrs, HR 0.41, 95% CI (0.30, 0.55), P < 0.001]. For the entire cohort, there was no difference in MST by treatment [4.6 yrs for PCV+RT vs. 4.7 yrs for RT, HR 0.79, 95% CI (0.60, 1.04), P = 0.1]. However, patients with 1p/19q co-deleted tumors lived much longer after PCV+RT (n = 59) than after RT (n = 67) [14.7 vs. 7.3 yrs, HR 0.59, 95% CI (0.37, 0.95), P = 0.03]. There was no difference in MST by treatment in pts without the 1p/19q co-deletion [n=137; 2.6 vs. 2.7 yrs, HR 0.85, 95% CI (0.58, 1.23), P = 0.39]. Re-operation rates upon progression were similar between treatment arms in co-deleted pts (43%, PCV+RT vs. 54%, RT) but salvage CT rates were higher in the RT arm [57% vs. 81% (P = 0.04)]. Conclusions: PCV followed by immediate RT was a highly effective therapy for patients with 1p/19q co-deleted AO/AOA. In this setting, 1p/19q co-deletion was both prognostic and predictive, and the early PFS benefit in co-deleted cases was a harbinger of their longer OS. [This work was supported by RTOG grants U10 CA21661 and U10 CA32115, NCCTG grant U10 CA25224, ECOG grants CA17145 and CA21115, SWOG grant CA32102, and CCOP grant U10 CA37422 from the National Cancer Institute (NCI)]
Leiomyoma of the Bladder
Knoll, L. Dean , Segura, Joseph W., Scheithauer, Bernd W.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 136 | Issue: 4 | Pages: 906-908

10.1016/s0022-5347(17)45124-x | PMID 3761457 Get It

Neuron-Specific Enolase in Neuroendocrine Tumors of the Thymus, Bronchus, and Skin
Scheithauer, Bernd W., Kovács, Kálmán, Wick, Mark R.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 131 | Issue: 1 | Pages: 184-184

10.1016/s0022-5347(17)50274-8 Get It

Atypical Teratoid/Rhabdoid Tumor with Ependymal Differentiation : A Case Report
Utsuki, Satoshi, Kaeano, Nobuyuki, Oka, Hidehiro, Saegusa, H, Fujii, Kiyotaka, Yagishita, Saburo, W., Scheithauer Bernd, W., Scheithauer Bernd

Mayo Clinic

Japanese Journal of Neurosurgery | June 2, 2017 | Volume: 7 | Issue: 8 | Pages: 507-512

10.7887/jcns.7.507 Get It

Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas
Smith, Justin S., Borell, Thomas J., Lee, Hyun K., OʼFallon, Judith R., Hosek, Sandra M., Kimmel, David W., Yates, Allan J., Burger, Peter C. , Scheithauer, Bernd W., Jenkins, Robert B. , Perry, Arie

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 3 | Pages: 636-636

10.1200/jco.2000.18.3.636 | PMID 10653879 Get It

PURPOSE: A recent report suggests that alterations of chromosome arms 1p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas. PATIENTS AND METHODS: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors. RESULTS: The oligodendroglial phenotype was highly associated with loss of 1p (P = .0002), loss of 19q (P < .0001), and combined loss of 1p and 19q (P < .0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log-rank, P = .03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P < .01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma. CONCLUSION: Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management.
Malignant Peripheral Nerve Sheath Tumor: An Immunohistochemical Study of 62 Cases
Scheithauer, Bernd W., Manivel, J. Carlos , Wick, Mark R. , Swanson, Paul E

Mayo Clinic

American Journal of Clinical Pathology | March 18, 2016 | Volume: 87 | Issue: 4 | Pages: 425-433

10.1093/ajcp/87.4.425 | PMID 2435144 Get It

Primary Neuroendocrine Carcinomas of the Skin (Merkel Cell Tumors): A Clinical, Histologic, and Ultrastructural Study of Thirteen Cases
Goellner, John R., Scheithauer, Bernd W., Thomas, J. R., Sánchez, Néstor P., Schroeter, Arnold L., Wick, Mark R.

Mayo Clinic

American Journal of Clinical Pathology | March 18, 2016 | Volume: 79 | Issue: 1 | Pages: 6-13

10.1093/ajcp/79.1.6 | PMID 6336886 Get It

Neuron-specific Enolase in Neuroendocrine Tumors of the Thymus, Bronchus, and Skin
Scheithauer, Bernd W., Kovács, Kálmán , Wick, Mark R.

Mayo Clinic

American Journal of Clinical Pathology | March 18, 2016 | Volume: 79 | Issue: 6 | Pages: 703-707

10.1093/ajcp/79.6.703 | PMID 6303108 Get It

Duodenal Gangliocytic Paraganglioma: Clinicopathologic and Immunocytochemical Study of 11 Cases
Scheithauer, Bernd W., Nora, Frederick E., Lechago, Juan, Crawford, Barbara G., Weiland, Louis H., Carney, J. Aidan, Wick, Mark R.

Mayo Clinic

American Journal of Clinical Pathology | March 17, 2016 | Volume: 86 | Issue: 5 | Pages: 559-565

10.1093/ajcp/86.5.559 | PMID 2877566 Get It